MacroGenics raih USD 10 juta setelah Gilead ambil lisensi eksklusif program bispesifik praklinis

Reuters2026/08/11 20:14

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

MacroGenics mengantongi pembayaran USD 10 juta usai Gilead mengeksekusi opsi lisensi program bispesifik praklinis dalam kolaborasi 2022.
Program berlisensi memakai platform TRIDENT, menargetkan dua target yang tidak diungkap untuk pengobatan tumor padat.
Dalam kerja sama itu, kedua perusahaan memajukan tiga program, termasuk MGD024, bispesifik CD123 × CD3 tahap klinis.
MacroGenics masih berhak atas hingga sekitar USD 1,6 miliar pembayaran milestone pengembangan, regulatori, komersial, serta royalti penjualan global.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MacroGenics Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

MacroGenics raih USD 10 juta setelah Gilead ambil lisensi eksklusif program bispesifik praklinis

You may also like

Crypto prices